A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
A phase 3 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Amgen, active and no longer recruiting.
Overview
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06311721 by Amgen, with 315 participants enrolled, started 2024-09-09 and due to reach its primary completion in 2028-01-10. Interventions recorded: ABP 234, Pembrolizumab (US), Pembrolizumab (EU). Conditions listed: Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialPharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
Shares Amgen, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants Wi
Shares Amgen, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
Shares Amgen, Small-cell lung cancer.
- TrialStudy Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
Shares Amgen, Small-cell lung cancer.
- TrialStudy Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
Shares Amgen, Small-cell lung cancer.
- TrialA Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
Shares Amgen, Small-cell lung cancer.
- TrialPhase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
Shares Amgen, Small-cell lung cancer.
- TrialStudy Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
Shares Amgen, Small-cell lung cancer.